FDA Panel Votes Against Primatene Reboot Due To Safety Concerns
This article was originally published in The Tan Sheet
Executive Summary
Concerns about safety prompt an FDA advisory panel to recommend against approving Armstrong Pharmaceutical’s NDA for an OTC emergency asthma inhaler. Concerns about device malfunction and about a potentially inaccurate dose indicator also influence the panel.